{"filing":{"accession_number":"0001193125-26-324174","cik":"0001498382","ticker":"HURA","company_name":"TuHURA Biosciences, Inc./NV","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-28","primary_document":"hura-20260728.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1498382/000119312526324174/hura-20260728.htm"},"events":[{"id":21764,"run_id":19633,"accession_number":"0001193125-26-324174","anchor_item_number":"2.03","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The Company drew an additional $1.5 million under an existing revolving credit facility on July 28, 2026. While the underlying Loan Agreement was previously disclosed on April 21, 2026, this Item 2.03 disclosure addresses the creation of a new direct financial obligation through the incremental draw. The filing explicitly states the Company \"received and borrowed an additional draw\" and references Item 2.03 (Creation of a Direct Financial Obligation), which is the standard Item for debt issuances and credit facility draws.","company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21477,"accession_number":"0001193125-26-324174","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company drew an additional $1.5 million under an existing revolving credit facility on July 28, 2026. While the underlying Loan Agreement was previously disclosed on April 21, 2026, this Item 2.03 disclosure addresses the creation of a new direct financial obligation through the incremental draw. The filing explicitly states the Company \"received and borrowed an additional draw\" and references Item 2.03 (Creation of a Direct Financial Obligation), which is the standard Item for debt issuances and credit facility draws.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:14:56.373464+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21477,"accession_number":"0001193125-26-324174","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company drew an additional $1.5 million under an existing revolving credit facility on July 28, 2026. While the underlying Loan Agreement was previously disclosed on April 21, 2026, this Item 2.03 disclosure addresses the creation of a new direct financial obligation through the incremental draw. The filing explicitly states the Company \"received and borrowed an additional draw\" and references Item 2.03 (Creation of a Direct Financial Obligation), which is the standard Item for debt issuances and credit facility draws.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:14:56.373464+00:00","company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","filing_date":"2026-07-29"}]}